Close menu




November 6th, 2020 | 11:04 CET

NEL ASA, Velocity Minerals, Barrick Gold - the next chance!

  • Innovations
Photo credits: pixabay.com

The market does what it wants. Anticipating a worst-case scenario, the markets drew a zig-zag ahead of Tuesday’s election but then settled back into a positive momentum. Dax alone made-up almost 700 points after the index plunged below 12,000 on Wednesday. Although the election spectacle is still not over, the stock markets are rising as if there were no tomorrow. On a positive note, gold has held on to its crucial support zone and is marching dynamically towards its all-time high. A breakout should be a matter of time.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA92258F3007 , NO0010081235 , CA0679011084

Table of contents:


    Gold mines explode

    Due to the rising gold price, first the gold mines of the first row like Barrick Gold, Iam Gold or Newcrest Mining, profit disproportionately. Should the gold price march consistently above the old highs, the leverage will lie instead with the smaller producers. The Canadian exploration Company, Velocity Minerals, is exciting. The Canadians are focused on the discovery and development of gold deposits in Bulgaria. Bulgaria is the country with the largest gold reserves in Europe. The Company's strategy is to develop a low-cost operation where multiple projects deliver gold concentrates to an existing central processing facility.

    Prospective drilling

    Velocity Minerals' flagship project is its 70% interest in Rozino. A PFS, Pre-Feasibility Study, was released last August. Gold mining production could start in 2022, with an after-tax internal rate of return of 27%, per annum! Yesterday, Velocity announced another milestone. In addition to Rozino, another coup appears to have been achieved on the Obichnik project. Both the two new drill holes tested from Premka Zone yielded high mineralization results.

    Golden Future

    President and CEO of Velocity Minerals commented: "The high-grade nature of the gold mineralization is very encouraging and there is more drilling to do at this target. We remain focused on building a multi-asset gold production profile in Bulgaria with a ‘Hub & Spoke’ development strategy. With the recent positive prefeasibility at the Rozino project, we continue to advance our exploration drill programs for resource expansion and definition at Rozino as well as the Obichnik, Makedontsi and Iglika projects."

    Numbers weak thanks to Nikola

    A successful hydrogen Company is in the red. How is that possible? In the case of the Norwegian showpiece Company, NEL ASA, it is due to the participation in the US truck builder Nikola, which still has to defend itself against massive fraud allegations. The negative market value adjustment of NOK 513.3 resulted in an EBITDA of NOK -42.1 million in the third quarter. Reported EBIT was NOK -116.3 million, while the pre-tax loss was NOK -628.6 million, as described above. In terms of turnover, the Scandinavian companies were able to maintain their turnover at NOK 147.7 million, roughly the same level as the previous year (NOK 148.9 million).

    Bright future

    NEL ASA was only able to show the positive trend in the hydrogen industry in terms of the order backlog. With an order backlog of NOK 940.0 million, the Company topped the previous year's figure by a whopping 60%. The coffers are full to the brim with NOK 2.5 billion, the equivalent of around EUR 230 million, to finance further dynamic growth.

    New prestige order

    Earlier this week, NEL ASA announced a significant order. None other than the Spanish utility giant Iberdrola selected the Norwegians as the preferred supplier for a 20-megawatt green fertilizer project in Spain. According to press reports, the plant is scheduled to go into operation as early as 2021. Iberdrola, one of the world's largest electricity suppliers, wants to build the largest environmentally friendly hydrogen plant in cooperation with fertilizer manufacturer, Fertiberia.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 24th, 2026 | 08:45 CEST

    AI and Chip Sell-Off! Watch Out for SMCI, AMD, and Infineon; First Hydrogen in the Innovation Race

    • Hydrogen
    • cleantech
    • chips
    • AI
    • Innovations
    • Software
    • semiconductor

    The stock market is currently showing no mercy. After months of gains in AI, high-tech, and chip stocks, the market has now shifted into profit-taking mode—and, at times, even sell-off mode. What analysts have been predicting for quite some time is increasingly coming to pass. The global stock market rally, driven by the NASDAQ, is taking its toll. While the long-term earnings outlook may be solid, short-term price surges of up to 2,000% in just 12 months no longer indicate a healthy market trend. So, while it comes as no surprise, it may be unwelcome for many market participants: a sharper downward move—one that, however, also brings new opportunities in its wake. We examine the fundamental framework of the key players and highlight alternatives for getting off to an innovative start today. The stock market keeps turning—just a little slower at times!

    Read

    Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST

    Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.

    Read

    Commented by Nico Popp on June 18th, 2026 | 07:35 CEST

    The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Innovations

    There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.

    Read